IP in a Post-pandemic World

Glargine Insulin: Prices People Pay

Antimicrobial Resistance: A Multifaceted Approach

Annual Report 2022

National diabetes programme: Tanzania’s Transition

Promoting Health Rights and Access to Medicines in Europe

Factsheet: The EU Medical Devices Regulation and the AI Act

Diagnostics to Address Antimicrobial Resistance


Snakebite Prevention: Safiya’s 8 Secrets

Licensing and Access to Health Technologies

The TRIPS Agreement Laid Bare

Missing Clinical Trial Data in Europe

Clinical Trial Regulation in Europe

Intergovernmental Negotiating Body Second Meeting – Statement

Religion and SRH: Role of faith leaders in Zambia & Burundi

Snakebite: Case Studies from Kajiado County, Kenya

HAI statement on the outcome of TRIPS negotiations at WTO MC12

HAI Statement to Intergovernmental Negotiating Body

Statement to WHA75 – Health Emergencies

Access to Insulin – What you need to know at WHA75

Diabetes Coverage Targets WHA75

Clinical Trial Integrity and COVID-19

Response to European Consultation on Compulsory Licensing

Annual Report 2021

Interpreting the EU Artificial Intelligence Act for the Health Sector

Pooled Procurement of Insulin & Associated Supplies


Report – Community Engagement Meeting on Snakebite Envenoming

Procurement of Insulins & Associated Supplies

Medicine Pricing and Access in Europe

Regulatory Profile for Glucose Self-monitoring Tools